The Analytical Center held a roundtable on “Creation of the Eurasian market for pharmaceutical products: pros and cons”, where experts discussed the conditions and prospects of creating a single market for pharmaceutical products for Russia, Kazakhstan and Belarus within the framework of the treaty on the establishment of the Eurasian Economic Union.
“Today, a new economic reality is forming on the Eurasian continent, in May of this year the treaty on the establishment of the Eurasian Economic Union was signed, which will come into force on 1 January, 2015, - said the Director of Eurasian communication center Aleksey Pilko, opening the roundtable. - This means that new common Eurasian markets for goods and services will be created”. According to him, pharmaceuticals industry is a capital intensive and promising direction, therefore now it is necessary to talk about the creation of the Eurasian market for pharmaceutical products and medical services.
Adviser to the Department of trade policy of the Eurasian Economic Commission Vitaly Ponomarev noted that the creation of the Eurasian pharmaceutical market is influenced by international activities of the Eurasian Economic Commission, first of all - the free trade area agreement under which work is organized within the Union. “By now, more than 30 countries have expressed their interest in creating a free trade area with the Russian Federation - said Mr. Ponomarev. - 10 of these states have already declared their readiness to discuss the issue of concluding an appropriate agreement with the states of the Eurasian Economic Union”. Adviser noted that negotiations for a free trade area with Vietnam are ongoing; a joint research group has been launched to study the practicability of entering into similar agreement with Israel; a decision to start collaboration with India has been taken. “Due to the fact that Israel and India are major pharmaceutical manufacturers and their share on the Russian market is big enough, it is necessary to work with the business community for maximizing benefits for our industry”, - believes Mr. Ponomarev. According to him, it is also necessary to prevent possible threats, for example, from the liberalization of the pharmaceutical products trade field, which may result from the signing of the present treaty.
According to Mr. Ponomarev, a free trade agreement and Russia's accession to the WTO - are completely different things. “WTO – is a package of certain agreements that are obligatory to follow - said the expert. - And the free trade agreement provides the opportunity for a wide range of actions; we have the necessary instruments for that”.
The roundtable participants agreed that the goal of all these activities is the recognition of the common registration certificates. According to them, it is necessary to adopt 25 documents of “second level” that will govern relations in 3 countries. Specialists consider that after that we can talk about mutual recognition of registration documents, but only for those drugs that are produced under the conditions of good manufacturing practices adopted by the Customs Union.
During the event, experts also pointed out the need to address the issue of pharmaceuticals quality control, as Russia, Kazakhstan and Belarus have completely different regulatory systems in this area.
The roundtable was jointly organized by the Analytical Center and the Eurasian communication center. Representatives of public authorities, manufacturers and distributors of pharmaceutical products, members of the expert and the professional community attended the event.